China Universal Asset Management Co. Ltd. lowered its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB - Free Report) by 58.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,200 shares of the company's stock after selling 6,000 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in Astera Labs were worth $699,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Nordea Investment Management AB bought a new stake in shares of Astera Labs in the fourth quarter valued at about $2,028,000. Geneva Partners LLC acquired a new stake in Astera Labs during the third quarter worth about $1,876,000. Numerai GP LLC increased its stake in Astera Labs by 153.1% during the third quarter. Numerai GP LLC now owns 13,212 shares of the company's stock valued at $2,587,000 after acquiring an additional 7,992 shares during the period. Handelsbanken Fonder AB increased its stake in Astera Labs by 289.5% during the third quarter. Handelsbanken Fonder AB now owns 126,200 shares of the company's stock valued at $24,710,000 after acquiring an additional 93,800 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in Astera Labs in the 2nd quarter valued at approximately $543,000. 60.47% of the stock is currently owned by institutional investors and hedge funds.
Astera Labs News Roundup
Here are the key news stories impacting Astera Labs this week:
Insider Activity at Astera Labs
In other Astera Labs news, Director Manuel Alba sold 183,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $107.61, for a total value of $19,692,630.00. Following the completion of the sale, the director owned 319,863 shares in the company, valued at approximately $34,420,457.43. This trade represents a 36.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Stefan A. Dyckerhoff sold 3,757 shares of the business's stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $175.12, for a total transaction of $657,925.84. Following the completion of the transaction, the director directly owned 67,144 shares of the company's stock, valued at approximately $11,758,257.28. This represents a 5.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,064,888 shares of company stock worth $150,764,723 in the last quarter. Insiders own 12.50% of the company's stock.
Astera Labs Stock Performance
Astera Labs stock opened at $212.84 on Friday. The firm has a market cap of $36.45 billion, a P/E ratio of 174.46, a P/E/G ratio of 3.89 and a beta of 1.78. The business's fifty day moving average is $133.87 and its two-hundred day moving average is $154.02. Astera Labs, Inc. has a 52 week low of $62.31 and a 52 week high of $262.90.
Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.07. Astera Labs had a return on equity of 16.12% and a net margin of 25.70%.The company had revenue of $270.58 million during the quarter, compared to analyst estimates of $249.46 million. During the same period last year, the company posted $0.37 earnings per share. The firm's quarterly revenue was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, equities research analysts predict that Astera Labs, Inc. will post 1.48 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts have commented on ALAB shares. Loop Capital began coverage on Astera Labs in a research report on Thursday, March 5th. They issued a "buy" rating and a $250.00 price objective for the company. Weiss Ratings cut Astera Labs from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, February 23rd. Barclays set a $165.00 target price on Astera Labs in a research report on Thursday, January 15th. Citigroup began coverage on shares of Astera Labs in a research note on Thursday, April 2nd. They set a "buy" rating and a $200.00 price target on the stock. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 price target on shares of Astera Labs in a report on Tuesday. Fifteen equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $199.74.
Check Out Our Latest Report on Astera Labs
Astera Labs Profile
(
Free Report)
Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.
The company's product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Astera Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astera Labs wasn't on the list.
While Astera Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.